ProstaLund AB is a Swedish medical technology company established in 1991 and based in Lund, Sweden. The company specializes in the development, manufacture, and sale of urological devices, particularly focusing on treatments for benign prostatic hyperplasia (BPH), a condition prevalent among men over 50 years old. Key products include the CoreTherm®, a patented thermotherapy treatment method for BPH; CoreFlow®, a temporary prostate stent designed to alleviate urinary symptoms; Oruflow, a urine flow meter for assessing urinary function; and the Schelin Catheter, used for intraprostatic and periprostatic drug injections. ProstaLund markets the CoreTherm® platform to clinics and hospitals and generates recurring revenue through the sale of disposable products used in BPH treatment. As of October 31, 2025, the company's stock price was SEK 0.2140, with a market capitalization of SEK 6.66 million. In 2024, ProstaLund reported SEK 13.73 million in revenue, marking a decrease of 37.79% from the previous year. The company employs between 9 and 13 individuals and is listed on the Nasdaq Stockholm under the ticker symbol PLUN. It holds a total of 28 patents and is a member of the Ideon Science Park in Lund.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
ProstaLund AB's offering is currently approved on OTHER. ProstaLund AB is headquartered in Sweden. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with ProstaLund AB.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/prostalund-ab" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="ProstaLund AB — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/prostalund-ab?theme=light as the src instead.
https://www.discoveripo.com/ipo/prostalund-ab/opengraph-image
ProstaLund AB IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/prostalund-ab?utm_source=embed&utm_medium=text&utm_campaign=prostalund-ab
Get emailed when ProstaLund AB's terms, price, or expected date change — no weekly noise, just this company.
ProstaLund AB is listing on OTHER.
ProstaLund AB is a Swedish medical technology company established in 1991 and based in Lund, Sweden. The company specializes in the development, manufacture, and sale of urological devices, particularly focusing on treatments for benign prostatic hyperplasia (BPH), a condition prevalent among men over 50 years old. Key products include the CoreTherm®, a patented thermotherapy treatment method for BPH; CoreFlow®, a temporary prostate stent designed to alleviate urinary symptoms; Oruflow, a urine flow meter for assessing urinary function; and the Schelin Catheter, used for intraprostatic and periprostatic drug injections. ProstaLund markets the CoreTherm® platform to clinics and hospitals and generates recurring revenue through the sale of disposable products used in BPH treatment. As of October 31, 2025, the company's stock price was SEK 0.2140, with a market capitalization of SEK 6.66 million. In 2024, ProstaLund reported SEK 13.73 million in revenue, marking a decrease of 37.79% from the previous year. The company employs between 9 and 13 individuals and is listed on the Nasdaq Stockholm under the ticker symbol PLUN. It holds a total of 28 patents and is a member of the Ideon Science Park in Lund.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy